William Kaelin, M.D.

William Kaelin

Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J. Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the […]

John Huynh, Ph.D.

John Huynh

John Huynh is the Chief Technology Officer at IconOVir Bio. He joins IconOVir from Ring Therapeutics, where he served as Senior Vice President of Technical Operations and was responsible for overseeing CMC development and manufacturing. Prior to joining Ring, he was a Vice President of Gene Therapy Technical Operations at PTC Therapeutics, where he helped […]

IconOVir Bio to Present at UBS Global Healthcare Conference

SAN DIEGO, CA., May 18, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Global […]

IconOVir Bio to Present at Jefferies Healthcare Conference

SAN DIEGO, CA., May 27, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare […]

IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042

Combined E1A and E4-ORF6/7 mutations demonstrate high degree of tumor selectivity in lead product candidate ICVB-1042 (formerly IOV-1042) IND filing for ICVB-1042 expected 1H 2022 Data published online in ASCO 2021 Annual Meeting Proceedings SAN DIEGO, CA., May 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic […]

IconOVir Bio Announces Formation of Scientific Advisory Board

Founding members bring deep expertise across interconnected fields of oncology research to provide strategic guidance and help advance programs into the clinic SAN DIEGO, CA., April 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced […]

Nicole van de Leuv

Nicole van de Leuv is Head of Legal at IconOVir Bio. Nicole also serves as a Principal at Two River, where she provides legal and operational support to Two River and its portfolio companies. Prior to joining Two River, Nicole was Special Counsel at Cooley LLP, where she focused on mergers and acquisitions and other […]

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Management Company, LLP and Logos Capital IconOVir formed by team behind Kite Pharma, Allogene Therapeutics and Kronos Bio Proprietary oncolytic virus platform based on technology developed at Salk Institute under the leadership of renowned […]

Clodagh O’Shea, Ph.D.

Clodagh O’Shea is the Scientific Founder of IconOVir Bio and Chair of IconOVir’s Scientific Advisory Board. She is also the Wicklow Capital Chair and Professor of Molecular and Cell Biology at the Salk Institute, a Howard Hughes Medical Institute Faculty Scholar, Allen Distinguished Investigator, Adjunct Professor at UCSD and Director of the Redesigning Biology and […]

Owen Witte, M.D.

Owen received his undergraduate degree from Cornell and his M.D. from Stanford University. He completed postdoctoral research at MIT, then joined the faculty at UCLA where he was recently appointed as University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Owen is also a […]